In This Section

Home / Blurb / Discussion List

FDA Expands Palbociclib Use to Include Male Breast Cancer Patients

Apr 5, 2019, 10:22 AM
On April 4, the U.S. Food and Drug Administration extended the indication of palbociclib (Ibrance, Pfizer Inc.) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

Read the full FDA press release here.

Posted 4/5/2019

Leave a comment